Bain Capital, LP is one of the world’s leading private investment firms with approximately $160 billion of assets under management that creates lasting impact for our investors, teams, businesses, and the communities in which we live. Since our founding in 1984, we’ve applied our insight and experience to organically expand into several asset classes including private equity, credit, public equity, venture capital and real estate. We leverage our shared platform to capture cross-asset class opportunities in strategic areas of focus. With offices on four continents, our global team aligns our interests with those of our investors for lasting impact.

Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact

Ron Renaud

Ron Renaud

Life Sciences


Mr. Renaud joined Bain Capital in 2022. He is Partner on the Bain Capital Life Sciences team. From 2014 to 2021, he was Chief Executive Officer of Translate Bio (Nasdaq: TBIO) which was acquired by Sanofi in 2021. Prior to that he was President and Chief Executive Officer of Idenix Pharmaceuticals (Nasdaq: IDIX) which was acquired by Merck in 2014. Prior to his career in the biotech industry, Ron was a biotechnology research analyst at JP Morgan and Bear Stearns. Earlier in his career, Ron held various roles at Amgen (Nasdaq: AMGN) as well as at the Dana-Farber Cancer Institute.


Mr. Renaud received an MBA from the University of Southern California Marshall School of Business and a BA from Saint Anselm College.